Augmentation Therapy in A1AT Deficiency

Indication Requirements

The American Thoracic Society/European Respiratory Society recommends augmentation therapy specifically for "severe hereditary deficiency of alpha1-antitrypsin (AAT) with clinically evident emphysema" 1, 2, 3
The American Thoracic Society/European Respiratory Society statement indicates that augmentation therapy is for patients with severe hereditary deficiency of alpha1-antitrypsin (AAT) and clinically evident emphysema, with a strength of evidence based on the 2003 guidelines 1, 2, 3

Evidence Hierarchy

The 2025 guidelines acknowledge a critical evidence gap: "it is not known whether augmentation therapy is beneficial for patients without impaired FEV1, nor whether earlier therapy would fully prevent lung function decline and impairment" 4
The benefit(s) of augmentation therapy for patients with A1AT deficiency and asthma with persistent airway obstruction and/or bronchiectasis but without CT scan evidence of emphysema are also unknown 4

Supporting Observational Data

The German-Danish study showed benefit only in patients with FEV1 31-65% predicted (moderate emphysema), with yearly FEV1 decline of -53 ml in treated vs -75 ml in untreated groups (p<0.02) 5, 6
The NHLBI Registry demonstrated mortality benefit (OR 0.79, p<0.02) and slowed FEV1 decline specifically in the subgroup with moderate emphysema (FEV1 35-49% predicted) 5, 6

Clinical Context and Pitfalls

A critical pitfall is assuming that A1AT deficiency diagnosis alone justifies augmentation therapy, as the rationale for augmentation is to prevent further lung destruction by restoring anti-elastase protection 1, 7

Diagnostic Requirements

High-resolution CT chest to document presence or absence of emphysema is required before approving augmentation therapy 8, 4
Pulmonary function testing with post-bronchodilator FEV1 is necessary to establish baseline lung function 5, 6
SERPINA1 gene sequencing is recommended to confirm the specific genetic variant before embarking on augmentation therapy 8, 4

Dosing Verification

The prescribed dose of 60 mg/kg weekly is appropriate and meets on-label dosing requirements, according to the American Journal of Respiratory and Critical Care Medicine 5, 6

Alternative Management

Pulmonary rehabilitation is recommended for symptomatic patients, as stated by the American Journal of Respiratory and Critical Care Medicine 7

Alpha-1 Antitrypsin Deficiency Treatment Guidelines

Diagnostic Approach

The American Thoracic Society conditionally recommends testing for A1AT deficiency in all individuals with COPD at diagnosis, those with adult-onset asthma with persistent airflow obstruction, and individuals with unexplained bronchiectasis 9
For patients with high clinical suspicion, both serum A1AT levels and genetic testing with DNA sequencing of SERPINA1 gene are recommended 9, 10

Treatment Algorithm

The American College of Chest Physicians conditionally recommends alpha-1 antitrypsin augmentation therapy for patients with COPD who have documented emphysema, FEV1 <80% predicted, severely reduced A1AT levels, and documented SERPINA1 genotypes associated with A1AT deficiency 11, 9
Never or previously smoked patients (must be smoke-free for at least 6 months) with FEV1 <80% predicted, documented emphysema, and documented SERPINA1 genotypes associated with A1AT deficiency are indicated for augmentation therapy 9, 12

Standard COPD Management

The American Thoracic Society recommends bronchodilators for symptomatic relief, even when objective bronchodilator responsiveness may be lacking 13
Inhaled steroids are recommended for those with bronchial hyperreactivity 13

Preventive Measures

Smoking cessation is critical, as early cessation significantly reduces FEV1 decline 12, 13
Influenza and pneumococcal vaccinations are recommended 12, 13

Special Considerations

Genetic testing is particularly important, as some variants may have normal A1AT levels but dysfunctional protein 9
Early diagnosis and treatment are crucial, as delayed diagnosis is associated with worse overall survival 11
Family screening should be considered for relatives of individuals identified with abnormal A1AT genes 10

Augmentation Therapy for Alpha-1 Antitrypsin Deficiency

Patient Eligibility Criteria

The American Thoracic Society/European Respiratory Society guidelines require patients to be current nonsmokers for at least 6 months before augmentation therapy initiation, as continued smoking accelerates emphysema progression and negates the protective benefits of augmentation therapy, making treatment futile 14, 15
Patients must be on optimal conventional COPD therapy, including inhaled bronchodilators, inhaled corticosteroids, preventive vaccinations, pulmonary rehabilitation, and supplemental oxygen, before augmentation therapy is considered, as augmentation therapy is NOT a replacement for standard COPD management but rather an adjunctive therapy for the underlying AAT deficiency 15, 14
A normal C-reactive protein level is required, as elevated CRP may indicate active inflammation or infection that could affect treatment decisions, and baseline inflammatory markers help establish treatment appropriateness and monitor response 15

Treatment Benefits and Risks

The strongest evidence for efficacy of augmentation therapy comes from patients with FEV1 31-65% predicted, with yearly FEV1 decline of -53 mL in treated versus -75 mL in untreated groups, and mortality benefit in the subgroup with FEV1 35-49% predicted 15
Evidence for benefit is weaker in patients with severe airflow obstruction, and augmentation therapy is specifically indicated for severe hereditary deficiency of alpha-1 antitrypsin with clinically evident emphysema 15, 14

Required Documentation and Safety Considerations

Documentation of smoking cessation, current COPD regimen, C-reactive protein level, IgA screening, CT chest, and vaccination status is required, as well as consideration of pulmonary rehabilitation referral if not already enrolled 15, 14
Absolute contraindications that must be ruled out include active smoking, IgA deficiency with anti-IgA antibodies, and lack of documented emphysema on imaging 15, 14

Laboratory Testing Prior to Alpha-1 Antitrypsin Augmentation Therapy

Essential Pre-Treatment Laboratory Tests

The American Thoracic Society recommends measuring serum A1AT protein level to be <11 mmol/L (0.57 g/L) before starting treatment, as this threshold defines severe deficiency eligible for augmentation therapy 16, 17
The Canadian Thoracic Society recommends SERPINA1 gene sequencing as the gold standard before embarking on A1AT replacement therapy, given the variability in A1AT protein serum levels and the existence of over 300 genetic variants 16, 18, 17
DNA sequencing is particularly critical because some genetic variants produce normal circulating A1AT levels by routine assays but the protein is nonfunctional, representing actual deficiency that would be missed by protein measurement alone 18

Pulmonary Function and Imaging Requirements

The American Thoracic Society recommends post-bronchodilator spirometry with FEV1 measurement to establish baseline lung function, as augmentation therapy is indicated only when FEV1 is <80% predicted 16, 17

Additional Required Documentation

The American Thoracic Society recommends verifying smoking status—patients must be nonsmokers for at least 6 months before therapy initiation, as continued smoking negates the protective benefits of augmentation therapy 16, 17
The American Thoracic Society recommends documenting Hepatitis A and B vaccination status, as the 2003 ATS/ERS guidelines recommend these vaccinations for individuals with A1AT deficiency 19
The American Thoracic Society recommends obtaining liver function tests (AST, ALT, bilirubin, alkaline phosphatase) as baseline, particularly in elderly individuals with A1AT deficiency 19

Critical Pitfalls to Avoid

The Canadian Thoracic Society emphasizes that genetic mutations are invariable, while A1AT levels may vary between repeat tests in the same individual, and some variants produce dysfunctional protein despite normal levels, highlighting the importance of genetic confirmation 16, 18, 17

Treatment of Alpha-1 Antitrypsin Deficiency

Diagnostic Confirmation and Treatment Eligibility

The Canadian Thoracic Society (2025) conditionally recommends augmentation therapy only when all criteria are met, including severe A1AT deficiency, documented SERPINA1 deficiency genotype, CT-documented emphysema, FEV1 <80% predicted, and smoke-free status for ≥6 months 20, 21
Genetic testing with SERPINA1 gene sequencing is mandatory before initiating augmentation therapy, as over 300 genetic variants exist and some produce normal circulating levels but dysfunctional protein 21
Severe deficiency threshold is defined as serum A1AT <11 mmol/L (<0.57 g/L) 20

Standard COPD Management

Pulmonary rehabilitation is recommended for functional impairment 22
Supplemental oxygen is indicated when standard criteria are met 20, 22

Augmentation Therapy

The American Thoracic Society and other guideline societies support the use of augmentation therapy for patients with severe A1AT deficiency, as it may slow the progression of emphysema 20, 21

Special Considerations

Anesthesia can be tolerated even with FEV1 <1.0 L if ventilation uses prolonged expiration time 22
Pregnancy carries increased risk of miscarriage and pneumothorax in patients with preexisting bullae 22
Air travel requires oxygen supplementation if predicted cabin pressure oxygen tension <55 mmHg 22

Alpha-1 Antitrypsin Replacement Therapy Indications

Core Eligibility Criteria

The Canadian Thoracic Society recommends that patients with COPD and severe A1AT deficiency (<11 mmol/L or <0.57 g/L) who have documented emphysema on CT scan, FEV1 <80% predicted, confirmed SERPINA1 deficiency genotypes, are never-smokers or former smokers (smoke-free ≥6 months), and are receiving optimal COPD therapy are eligible for A1AT augmentation therapy 23, 24
Severe A1AT deficiency is defined as a serum A1AT level <11 mmol/L (<0.57 g/L) 23, 24, 25
Genetic confirmation of SERPINA1 deficiency genotypes (typically Pi*ZZ, but requires DNA sequencing confirmation) is required for A1AT augmentation therapy 23, 24
Impaired lung function, defined as post-bronchodilator FEV1 <80% predicted, is a requirement for A1AT augmentation therapy 23, 24, 25
Patients must be never-smokers or former smokers who have been smoke-free for at least 6 months to be eligible for A1AT augmentation therapy 24
Optimal baseline therapy, including bronchodilators, inhaled corticosteroids, vaccinations, pulmonary rehabilitation, supplemental oxygen (if indicated), and comprehensive case management, is required for A1AT augmentation therapy 23, 25, 26

Evidence Quality and Strength of Recommendation

The recommendation for A1AT augmentation therapy is conditional, based on high-quality evidence for CT lung density preservation but very low-quality evidence for mortality benefit 24

Conditions NOT Indicated for Augmentation Therapy

The Canadian Thoracic Society guideline explicitly states that augmentation therapy does not address A1AT deficiency-related liver disease, necrotizing panniculitis, or anti-neutrophil-cytoplasmic antibody-positive vasculitis 23, 26, 27

Diagnostic Workup Required Before Therapy

Serum A1AT level must be <11 mmol/L (<0.57 g/L) to meet severe deficiency threshold 23, 24, 25
DNA sequencing is required to confirm SERPINA1 deficiency genotypes 28

Special Considerations

Do not rely solely on serum A1AT levels for diagnosis, as levels can fluctuate during acute inflammation or infection 28
DNA sequencing is mandatory because some genetic variants produce normal serum levels but dysfunctional protein 28

Alpha‑1 Antitrypsin Augmentation Therapy for Severe Deficiency

Eligibility Criteria

Initiate weekly intravenous alpha‑1 antitrypsin (A1AT) augmentation at 60 mg/kg in adults who have severe A1AT deficiency (serum A1AT < 11 mmol/L or < 0.57 g/L), a documented pathogenic SERPINA1 genotype, CT‑confirmed emphysema, post‑bronchodilator FEV₁ < 80 % predicted, are never‑smokers or former smokers who have been smoke‑free for ≥ 6 months, and are already receiving optimal conventional COPD therapy (inhaled bronchodilators ± inhaled corticosteroids, influenza and pneumococcal vaccination, supplemental oxygen if needed)【29】【30】【31】【32】.
Serum A1AT level must be below 11 mmol/L (0.57 g/L) to meet the severe‑deficiency threshold【29】【31】【32】.
Post‑bronchodilator spirometry must demonstrate FEV₁ < 80 % predicted【31】【32】.
Patients with FEV₁ ≥ 80 % predicted have no established benefit from augmentation therapy【31】【32】.

Diagnostic Confirmation

SERPINA1 gene sequencing is required for diagnosis because > 300 variants exist, some of which produce normal circulating A1AT levels but dysfunctional protein【33】.

Dosing Regimen

60 mg/kg body weight is administered intravenously once weekly at an infusion rate ≤ 0.2 mL/kg/min (adjusted for tolerance). This regimen maintains trough serum A1AT concentrations above the protective threshold of 11 mmol/L【29】.

Evidence of Efficacy

Patients with moderate emphysema (FEV₁ 31‑65 % predicted) show the greatest benefit: annual FEV₁ decline of –53 mL with therapy versus –75 mL without therapy (p < 0.02)【29】.
The RAPID trial demonstrated a significant slowing of CT‑derived lung‑density loss over 2 years, with modelled extrapolation suggesting ≈ 6 years longer survival before death or lung transplantation if therapy is continued【29】.